Drug intelligence / Profile preview

CranEx

Development stage: Unknown
Lead developer: PharmaPrint
Administration: Oral

Overview

CranEx is a dietary supplement developed and marketed by PharmaPrint. It is part of a product line that includes other standardized herbal extracts such as AcuiT and BluEx. Based on its name and the manufacturer's focus, CranEx is a cranberry-based extract intended to support urinary tract health. The product was developed using PharmaPrint's proprietary technology designed to standardize the active components of herbal medicines to ensure consistent potency and quality. It is sold directly to consumers as a nutraceutical and is not classified as a regulated pharmaceutical drug.

Brand names: CranEx

Beyond the preview

Go deeper on CranEx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CranEx.

Explore the full profile